EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieÄquivalenzstudieOpen Access · CC BY-NC 4.0

A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes ( AWARD‐JPN )

Tomoaki Morioka, Masakazu Takeuchi iD, Akichika Ozeki, Masanori Emoto

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15644 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Tomoaki Morioka und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Glycated Hemoglobin. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly Japan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the efficacy and safety of dulaglutide 1.5 mg versus dulaglutide 0.75 mg in Japanese participants with type 2 diabetes (T2D). Materials and Methods A Phase 3, multicentre, randomized, double‐blind, parallel‐group study was conducted in Japanese participants aged ≥20 years, with T2D for ≥6 months and inadequate glycaemic control, while on a single oral antihyperglycaemic medication (NCT04809220). The primary objective was to evaluate superiority of dulaglutide 1.5 mg versus dulaglutide 0.75 mg measured by mean change in glycated haemoglobin (HbA1c) from baseline to 26 weeks. Other efficacy and safety endpoints were evaluated at 26 and 52 weeks. All statistical analyses were conducted using the intention‐to‐treat population.

Results

Overall, 591 participants were randomized to once‐weekly dulaglutide 1.5 mg or 0.75 mg. At Week 26, dulaglutide 1.5 mg was superior to dulaglutide 0.75 mg in HbA1c reduction from baseline (least squares mean [LSM] difference −0.29% [95% confidence interval {CI} −0.43, −0.14]). At Week 52, the dulaglutide 1.5‐mg arm had a significantly greater proportion of participants who achieved HbA1c

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood GlucoseDiabetes Mellitus, Type 2Glucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsAdultAgedFemaleHumansMaleMiddle AgedDouble-Blind MethodDrug Administration ScheduleEast Asian PeopleHypoglycemiaJapanTreatment OutcomeYoung Adult

Stichwörter der Autor:innen

GLP‐1dulaglutidephase III studyrandomized trialtype 2 diabetes

Substanzen

Blood GlucosedulaglutideGlucagon-Like PeptidesGlycated Hemoglobinhemoglobin A1c protein, humanHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Metabolism, Endocrinology, and Molecular Medicine, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
  • Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K., Kobe, Japan.

ORCID-Profile: Masakazu Takeuchi

Förderung

  • Eli Lilly Japan

Zitieren

APA

Morioka, T., Takeuchi, M., Ozeki, A., & Emoto, M. (2024). A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes ( AWARD‐JPN ). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15644

Vancouver

Morioka T, Takeuchi M, Ozeki A, Emoto M. A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes ( AWARD‐JPN ). Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15644

BibTeX
@article{Morioka2024,
  author = {Morioka, Tomoaki and Takeuchi, Masakazu and Ozeki, Akichika and Emoto, Masanori},
  title = {A randomized, double‐blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes ( AWARD‐JPN )},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15644}
}
Kostenlos starten →